F-Prime Capital

Notabene, Inc. is a New York-based company founded in 2020 that specializes in developing a software as a service (SaaS) platform for crypto compliance tailored for the financial industry. The company focuses on helping financial institutions adhere to emerging global regulations concerning cryptocurrency transactions, specifically addressing the complexities of the Travel Rule. Notabene offers a unified API and dashboard designed to assist compliance officers in managing risk associated with both Travel Rule and non-custodial transactions. By providing access to a broad network of crypto businesses, Notabene simplifies the compliance process, enhances transaction confidence, and ultimately supports its clients in increasing their transaction volumes and business growth.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.

Canoe Software Inc. provides a sophisticated software solution focused on financial document and data management. Founded in 2013 and based in New York, the company specializes in automating the extraction and organization of investment documents using artificial intelligence and machine learning technologies. This enables users to efficiently convert unstructured data from various formats, such as PDFs, into actionable insights, thereby improving operational efficiency. Canoe's platform supports a wide range of clients, including single and multi-family offices, endowments, foundations, pensions, investment consultants, and financial institutions, facilitating better management of post-investment operations, monitoring, and reporting. By streamlining the data management process, Canoe helps minimize manual data entry and enhances the accuracy of financial reporting and analysis.

Founded in 2015 by Dr. Robert Schoelkopf, Quantum Circuits develops and manufactures quantum computers based on superconducting devices. The company focuses on creating full-stack quantum computers designed for efficient scaling, with a pioneering approach to error detection and correction.

Doceree is a healthcare marketing technology company that provides a platform and solutions to help pharmaceutical and healthcare brands reach healthcare professionals. Its programmatic platform supports physician engagement and targeted advertising across physician networks, medical journals, telemedicine platforms, and relevant digital channels, delivering compliant, scalable messages. The platform uses artificial intelligence, data segmentation, and analytics to identify target healthcare professionals and optimize reach across global digital ecosystems. Doceree serves pharmaceutical brands, medical device brands, consumer health brands, hospitals, and media agencies, enabling access to physician-only environments and enabling compliant engagement at scale.

Better Life Partners Inc. is a healthcare company based in Hanover, New Hampshire, dedicated to providing comprehensive support for individuals struggling with opioid use disorder in the United States. Established in 2018, the company offers a range of services, including medication-assisted treatment, counseling, peer coaching, and group sessions. Better Life Partners focuses on delivering personalized healthcare to vulnerable populations, utilizing technology to create customizable care plans that ensure effective and reliable service delivery. By integrating medical and behavioral healthcare, the company addresses the needs of those affected by addiction, facilitating their recovery through a combination of telehealth, community-based support, and innovative care approaches. With additional offices across New Hampshire, Better Life Partners aims to make a meaningful impact on the lives of individuals seeking to overcome substance abuse challenges.

Simon Data develops a customer data platform designed to enhance campaign performance via precise segmentation and personalization. Its platform identifies purchase intent, predicts churn, estimates customer lifetime value, and enables brands to deliver personalized experiences across channels.

Founded in 2017, 1upHealth operates a health data aggregation platform that securely centralizes patient records from various electronic medical systems. Its platform enables patients to control and share their consolidated digital health record with providers, while also allowing developers to access clinical data from connected clinics and hospitals.

Zus Health is a healthcare technology company founded in 2020 by Jonathan Bush, based in Watertown, Massachusetts. It specializes in developing a healthcare data platform that accelerates the creation of digital health solutions. The platform uniquely integrates health and non-health information, allowing healthcare professionals to gain a comprehensive understanding of patients while sharing clinical and non-clinical data without requiring the same applications. By removing traditional barriers, Zus Health empowers a new generation of healthcare builders to design technologies and services that are more affordable and customizable, aiming to enhance the overall healthcare experience.

Canoe Software Inc. provides a sophisticated software solution focused on financial document and data management. Founded in 2013 and based in New York, the company specializes in automating the extraction and organization of investment documents using artificial intelligence and machine learning technologies. This enables users to efficiently convert unstructured data from various formats, such as PDFs, into actionable insights, thereby improving operational efficiency. Canoe's platform supports a wide range of clients, including single and multi-family offices, endowments, foundations, pensions, investment consultants, and financial institutions, facilitating better management of post-investment operations, monitoring, and reporting. By streamlining the data management process, Canoe helps minimize manual data entry and enhances the accuracy of financial reporting and analysis.

Founded in 2016, Firefly Health delivers AI-driven virtual-first primary care. Its platform connects patients with healthcare professionals for convenient, continuous care, focusing on common conditions and women's health issues.

Founded in 2019, Vendr is a SaaS-based platform that streamlines software procurement for businesses. It offers services such as commercial negotiations, renewal management, and contract logistics to help companies efficiently manage their software purchases.

Proximie is a health technology company that enables surgeons worldwide to collaborate remotely using augmented reality, artificial intelligence, and machine learning. Its platform allows surgeons to visually guide complex surgeries, democratizing access to advanced surgical knowledge.

Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, specializing in the development of protein-based therapeutics for animal health care and veterinary medicine. The company employs a team of veterinary scientists and clinicians dedicated to the discovery and development of biotherapeutics for both pets and farm animals. Invetx aims to transform the animal health industry by leveraging biopharmaceutical technologies to improve health outcomes significantly. By combining deep expertise in veterinary science with innovative therapeutic solutions, Invetx seeks to advance the future of animal care, providing effective treatments that cater to the needs of various animal populations.

Doceree is a healthcare marketing technology company that provides a platform and solutions to help pharmaceutical and healthcare brands reach healthcare professionals. Its programmatic platform supports physician engagement and targeted advertising across physician networks, medical journals, telemedicine platforms, and relevant digital channels, delivering compliant, scalable messages. The platform uses artificial intelligence, data segmentation, and analytics to identify target healthcare professionals and optimize reach across global digital ecosystems. Doceree serves pharmaceutical brands, medical device brands, consumer health brands, hospitals, and media agencies, enabling access to physician-only environments and enabling compliant engagement at scale.

RightHand Robotics, Inc. is a manufacturer of robotic order-picking systems that streamline supply chain logistics for various industries, including e-commerce, food handling, and flexible manufacturing. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company specializes in robotic solutions that automatically grasp a wide variety of items from bins and cases. Its flagship products include the ReFlex SF, which features a 3D-printed palm equipped with servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor designed to enhance the robots' ability to handle items gently and correct errors. RightHand Robotics focuses on providing end-to-end solutions that simplify integration and adaptation to diverse customer workflows, ultimately reducing the costs associated with order fulfillment across sectors such as electronics, apparel, grocery, and pharmaceuticals.

Notabene, Inc. is a New York-based company founded in 2020 that specializes in developing a software as a service (SaaS) platform for crypto compliance tailored for the financial industry. The company focuses on helping financial institutions adhere to emerging global regulations concerning cryptocurrency transactions, specifically addressing the complexities of the Travel Rule. Notabene offers a unified API and dashboard designed to assist compliance officers in managing risk associated with both Travel Rule and non-custodial transactions. By providing access to a broad network of crypto businesses, Notabene simplifies the compliance process, enhances transaction confidence, and ultimately supports its clients in increasing their transaction volumes and business growth.

Founded in 2014 by Fredrik Skantze and Per Made, Funnel is a software company specializing in marketing analytics. It integrates with over 400 data sources to automate data collection from various advertising platforms, catering to e-commerce companies, media agencies, brands, B2B businesses, mobile apps, and gaming companies.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.

Carrot Fertility, Inc. offers comprehensive fertility benefits services for employers, supporting employees throughout their fertility healthcare journey on a global scale. Founded in 2015 and headquartered in San Francisco, California, the company provides a range of services including egg freezing, in vitro fertilization, adoption, donor and gestational carrier services. It also features Carrot Rx, a premium pharmacy experience for fertility medications, and Carrot Pregnancy, which offers virtual access to experts and on-demand doctor-approved content. Additionally, Carrot Card is a flexible debit card that employees can use to pay for fertility care. Carrot Fertility aims to help companies customize their fertility benefits, ensuring that employees receive the necessary financial, medical, and emotional support as they pursue parenthood. The company has expanded its presence with additional offices in major cities including Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

Zus Health is a healthcare technology company founded in 2020 by Jonathan Bush, based in Watertown, Massachusetts. It specializes in developing a healthcare data platform that accelerates the creation of digital health solutions. The platform uniquely integrates health and non-health information, allowing healthcare professionals to gain a comprehensive understanding of patients while sharing clinical and non-clinical data without requiring the same applications. By removing traditional barriers, Zus Health empowers a new generation of healthcare builders to design technologies and services that are more affordable and customizable, aiming to enhance the overall healthcare experience.

Affinia Therapeutics develops adeno-associated virus (AAV) gene therapies for muscular and central nervous system diseases. The company uses an AAV vector design platform built on synthetic and systems biology, high-throughput screening, and tissue- and single-cell-resolution analyses to create vectors with improved properties. It leverages sequencing, artificial intelligence, and structural modeling to enable rational design of therapies. Headquartered in Waltham, Massachusetts, Affinia Therapeutics was founded in 2019 and targets diseases with significant unmet needs in muscle and CNS.

Proximie is a health technology company that enables surgeons worldwide to collaborate remotely using augmented reality, artificial intelligence, and machine learning. Its platform allows surgeons to visually guide complex surgeries, democratizing access to advanced surgical knowledge.

Founded in 2017, 1upHealth operates a health data aggregation platform that securely centralizes patient records from various electronic medical systems. Its platform enables patients to control and share their consolidated digital health record with providers, while also allowing developers to access clinical data from connected clinics and hospitals.

Founded in 2016, Firefly Health delivers AI-driven virtual-first primary care. Its platform connects patients with healthcare professionals for convenient, continuous care, focusing on common conditions and women's health issues.

Founded in 2019, Vendr is a SaaS-based platform that streamlines software procurement for businesses. It offers services such as commercial negotiations, renewal management, and contract logistics to help companies efficiently manage their software purchases.

Cohort, Inc. is a software company focused on enhancing chronic care management and clinical trial processes. Based in New York with an additional office in San Francisco, the company utilizes clinical artificial intelligence and natural language processing to analyze electronic health records. This analysis includes evaluating diagnostics, medications, and clinical notes to provide context relevant to specific patients and their conditions. Cohort’s software streamlines the identification and enrollment of eligible patients, generates tailored care plans, and automates compliance and billing tasks. The company’s solutions are designed to enable Primary Care Providers to improve the scale, efficiency, and outcomes of their Chronic Care Management programs while facilitating clinical trial identification and enrollment.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.

Carrot Fertility, Inc. offers comprehensive fertility benefits services for employers, supporting employees throughout their fertility healthcare journey on a global scale. Founded in 2015 and headquartered in San Francisco, California, the company provides a range of services including egg freezing, in vitro fertilization, adoption, donor and gestational carrier services. It also features Carrot Rx, a premium pharmacy experience for fertility medications, and Carrot Pregnancy, which offers virtual access to experts and on-demand doctor-approved content. Additionally, Carrot Card is a flexible debit card that employees can use to pay for fertility care. Carrot Fertility aims to help companies customize their fertility benefits, ensuring that employees receive the necessary financial, medical, and emotional support as they pursue parenthood. The company has expanded its presence with additional offices in major cities including Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

Founded in 2014, Compass Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics to treat solid tumors and hematological malignancies. Its pipeline includes CTX-471, an agonistic antibody of CD137 for immune cell activation, currently in Phase I trials; CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, in IND-enabling studies; and CTX-009, a bispecific antibody inhibiting DLL4 and VEGF-A signaling, completed Phase I and is in Phase Ib combination with chemotherapy.

RightHand Robotics, Inc. is a manufacturer of robotic order-picking systems that streamline supply chain logistics for various industries, including e-commerce, food handling, and flexible manufacturing. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company specializes in robotic solutions that automatically grasp a wide variety of items from bins and cases. Its flagship products include the ReFlex SF, which features a 3D-printed palm equipped with servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor designed to enhance the robots' ability to handle items gently and correct errors. RightHand Robotics focuses on providing end-to-end solutions that simplify integration and adaptation to diverse customer workflows, ultimately reducing the costs associated with order fulfillment across sectors such as electronics, apparel, grocery, and pharmaceuticals.

Founded in 2018, Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. The company aims to reprogram cells in the body or replace damaged ones to treat a broad range of diseases, with a pipeline including SC291, SC262, SC255, UP421, and other candidates across therapeutic areas like oncology, diabetes, autoimmune disorders, and CNS.

Verve Therapeutics is a biotechnology company developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic management to single-course gene editing therapies. It leverages human genetics analysis and gene-editing technology, with expertise in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.

NFlection Therapeutics, Inc. is a biotechnology company dedicated to discovering and developing targeted therapies for rare disorders, particularly focusing on neurofibromatosis type 1 and related conditions. The company specializes in addressing diseases driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway, including cutaneous neurofibromas and other conditions such as immunosuppressant-mediated squamous cell carcinoma and congenital birthmarks. NFlection Therapeutics is known for its innovative approach to drug formulation, offering treatments in a cosmetically elegant gel that can be applied topically, allowing for localized suppression of the Ras pathway while minimizing systemic side effects associated with oral medications. Established in 2014, the company is headquartered in Wayne, Pennsylvania.

PatientPing, Inc. is a health technology company that has developed a national care coordination network aimed at enhancing communication among healthcare providers. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers real-time notifications and care guidelines to various healthcare professionals, including physicians, nurses, case managers, and care coordinators. This network spans hospitals, emergency departments, accountable care organizations, physician practices, skilled nursing facilities, home health agencies, and payers. PatientPing's platform includes a tool called Spotlights, which leverages real-time data to analyze utilization and performance trends in patient care. By improving information sharing among care teams, PatientPing facilitates higher quality, cost-effective care, ultimately aiming to enhance patient outcomes and experiences. The company also maintains a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC.

NodThera is a UK-based biotechnology company focused on developing novel inhibitors of the NLRP3 inflammasome for treating inflammatory and neuroinflammatory diseases. Established in 2016, it operates laboratories in Little Chesterford (UK) and Seattle (US), with corporate offices in Lexington (US). The company's primary research involves inflammasomes, multi-protein complexes targeting conditions such as arthritis, atherosclerosis, Alzheimer's disease, diabetes, and certain cancers.

Founded in 2016, Owkin is a French-American startup that uses artificial intelligence to enhance medical research. It develops machine learning tools to understand complex biology, identify new treatments, de-risk clinical trials, and develop diagnostics. Owkin's focus is improving drug discovery processes and patient outcomes.

Rallybio is a clinical-stage biopharmaceutical company focused on developing therapies for severe and rare diseases. Its programs cover hematology, immuno-inflammation, maternal-fetal health and metabolic disorders, with a lead candidate aimed at preventing fetal and neonatal alloimmune thrombocytopenia, a life-threatening condition that can cause bleeding in fetuses and newborns. Founded in 2018 and based in New Haven, Connecticut, Rallybio develops therapies across antibodies, small molecules and engineered proteins to address unmet needs in rare diseases. Guided by experienced biopharma leadership, the company emphasizes translating biology into transformative therapies for underserved patients.

Affinia Therapeutics develops adeno-associated virus (AAV) gene therapies for muscular and central nervous system diseases. The company uses an AAV vector design platform built on synthetic and systems biology, high-throughput screening, and tissue- and single-cell-resolution analyses to create vectors with improved properties. It leverages sequencing, artificial intelligence, and structural modeling to enable rational design of therapies. Headquartered in Waltham, Massachusetts, Affinia Therapeutics was founded in 2019 and targets diseases with significant unmet needs in muscle and CNS.

B-One Ortho Corp. is a manufacturer of orthopedic healthcare solutions, specializing in artificial joints that facilitate joint replacement surgeries. Founded in 2015 and headquartered in Cedar Knolls, New Jersey, the company also maintains offices in Shanghai and Suzhou, China. Its notable products include the B-One total hip system, which features advanced coating technology and instrumentation, as well as the Juveno bone-conserving femoral prosthesis and primary acetabular systems. These innovations aim to enhance the effectiveness of hip and knee arthroplasty, ultimately helping patients regain their mobility and improve their quality of life.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Founded in 2014 by Fredrik Skantze and Per Made, Funnel is a software company specializing in marketing analytics. It integrates with over 400 data sources to automate data collection from various advertising platforms, catering to e-commerce companies, media agencies, brands, B2B businesses, mobile apps, and gaming companies.

Wellframe Inc. is a Boston-based company that specializes in digital care management and health advocacy solutions. Founded in 2011, it partners with health plans across the country to enhance the relationship between healthcare providers and members. Wellframe's offerings include a mobile application that facilitates daily health reporting, a care team dashboard to prioritize patient needs, and an array of communication tools for two-way messaging. The company also provides comprehensive operational services, such as implementation support, recruiting, and analytics. Additionally, Wellframe's platform employs real-time data and artificial intelligence to deliver personalized care protocols, enabling caregivers to monitor patient status effectively and identify when intervention is necessary. By focusing on mobile patient engagement and care management, Wellframe aims to improve health outcomes and empower individuals in managing their health.

Founded in 2019, Vendr is a SaaS-based platform that streamlines software procurement for businesses. It offers services such as commercial negotiations, renewal management, and contract logistics to help companies efficiently manage their software purchases.

Founded in 2016, Firefly Health delivers AI-driven virtual-first primary care. Its platform connects patients with healthcare professionals for convenient, continuous care, focusing on common conditions and women's health issues.

Simon Data develops a customer data platform designed to enhance campaign performance via precise segmentation and personalization. Its platform identifies purchase intent, predicts churn, estimates customer lifetime value, and enables brands to deliver personalized experiences across channels.

Buoy Health is a health technology company that develops AI-powered digital health tools to help individuals manage healthcare options. It offers an online healthcare assistant that analyzes symptoms, performs first-line triage, and provides treatment recommendations. Its platform delivers real-time symptom analysis and helps users navigate the healthcare system, research benefits, and locate in-network providers. For employers, the platform surfaces benefits information, guides employees to in-network providers, and integrates with other health portals. Founded in 2014 and based in Boston, Buoy Health aims to resemble a physician-patient conversation through machine learning and proprietary data, enabling users to make informed care decisions.

Founded in 2014, Quartet Health operates a cloud-based platform facilitating communication between medical providers and behavioral health specialists for improved patient care. The platform works with health plans and systems to provide actionable insights on behavioral health conditions, enhancing patient outcomes.

Verve Therapeutics is a biotechnology company developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic management to single-course gene editing therapies. It leverages human genetics analysis and gene-editing technology, with expertise in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

Optimus Ride is a self-driving vehicle company located in Boston, Massachusetts, focused on developing technologies that promote efficient, sustainable, and equitable mobility systems. As a spinoff from the Massachusetts Institute of Technology, the company leverages over 30 years of interdisciplinary research in self-driving technologies, electric vehicles, and Mobility-on-Demand Systems. Optimus Ride specializes in creating self-driving technology systems tailored for geofenced environments, utilizing innovations in complex sensor fusion, mapping, computer vision, and machine learning. The company's expertise is further enhanced by a team with extensive industrial and entrepreneurial experience in manufacturing robots, urban design, and shared vehicle fleet management, allowing it to offer versatile transportation solutions that range from commercial vessel operations to transit options.

Founded in 2016, Owkin is a French-American startup that uses artificial intelligence to enhance medical research. It develops machine learning tools to understand complex biology, identify new treatments, de-risk clinical trials, and develop diagnostics. Owkin's focus is improving drug discovery processes and patient outcomes.

Beam Therapeutics is a biotechnology company developing precision genetic medicines using its proprietary base editing technology. Its focus includes therapies for hematological and genetic diseases, with ongoing programs targeting sickle cell disease, alpha-1 antitrypsin deficiency, and other serious conditions.

Founded in 2018, Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. The company aims to reprogram cells in the body or replace damaged ones to treat a broad range of diseases, with a pipeline including SC291, SC262, SC255, UP421, and other candidates across therapeutic areas like oncology, diabetes, autoimmune disorders, and CNS.

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

B-One Ortho Corp. is a manufacturer of orthopedic healthcare solutions, specializing in artificial joints that facilitate joint replacement surgeries. Founded in 2015 and headquartered in Cedar Knolls, New Jersey, the company also maintains offices in Shanghai and Suzhou, China. Its notable products include the B-One total hip system, which features advanced coating technology and instrumentation, as well as the Juveno bone-conserving femoral prosthesis and primary acetabular systems. These innovations aim to enhance the effectiveness of hip and knee arthroplasty, ultimately helping patients regain their mobility and improve their quality of life.

TraceLink develops and provides track-and-trace solutions for the life sciences supply chain. Its primary offering is TraceLink Life Sciences Cloud, enabling pharmaceutical serialization and compliance with regulations like EU Falsified Medicines Directive. The company serves pharmaceutical companies, distributors, and repackagers, with strategic partnerships to enhance its services.

Axoni is a technology company specializing in real-time data replication solutions tailored for the financial industry. Established in 2017, it focuses on serving major financial institutions, including banks, asset managers, hedge funds, and market infrastructure firms worldwide, with offices located in New York and London. The company's platform facilitates the rapid and reliable deployment of critical financial networks, ensuring automated, real-time data replication among market participants. Additionally, Axoni develops distributed ledger software that integrates traditional financial technologies with blockchain capabilities, enhancing market information, trend analysis, and communication networks. This innovative approach allows financial entities to modernize their systems related to legal records, lifecycle events, and cash flow calculations, thereby improving operational efficiency and data management.

Simon Data develops a customer data platform designed to enhance campaign performance via precise segmentation and personalization. Its platform identifies purchase intent, predicts churn, estimates customer lifetime value, and enables brands to deliver personalized experiences across channels.

Flywire facilitates global payments for educational institutions and their students worldwide. It offers a secure platform supporting diverse payment methods in over 140 currencies across 240 countries.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.

Founded in 2014, Compass Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics to treat solid tumors and hematological malignancies. Its pipeline includes CTX-471, an agonistic antibody of CD137 for immune cell activation, currently in Phase I trials; CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, in IND-enabling studies; and CTX-009, a bispecific antibody inhibiting DLL4 and VEGF-A signaling, completed Phase I and is in Phase Ib combination with chemotherapy.

Founded in 2018, Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. The company aims to reprogram cells in the body or replace damaged ones to treat a broad range of diseases, with a pipeline including SC291, SC262, SC255, UP421, and other candidates across therapeutic areas like oncology, diabetes, autoimmune disorders, and CNS.

NodThera is a UK-based biotechnology company focused on developing novel inhibitors of the NLRP3 inflammasome for treating inflammatory and neuroinflammatory diseases. Established in 2016, it operates laboratories in Little Chesterford (UK) and Seattle (US), with corporate offices in Lexington (US). The company's primary research involves inflammasomes, multi-protein complexes targeting conditions such as arthritis, atherosclerosis, Alzheimer's disease, diabetes, and certain cancers.

TraceLink develops and provides track-and-trace solutions for the life sciences supply chain. Its primary offering is TraceLink Life Sciences Cloud, enabling pharmaceutical serialization and compliance with regulations like EU Falsified Medicines Directive. The company serves pharmaceutical companies, distributors, and repackagers, with strategic partnerships to enhance its services.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Beam Therapeutics is a biotechnology company developing precision genetic medicines using its proprietary base editing technology. Its focus includes therapies for hematological and genetic diseases, with ongoing programs targeting sickle cell disease, alpha-1 antitrypsin deficiency, and other serious conditions.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Founded in 2014, Quartet Health operates a cloud-based platform facilitating communication between medical providers and behavioral health specialists for improved patient care. The platform works with health plans and systems to provide actionable insights on behavioral health conditions, enhancing patient outcomes.

Valor Performance, Inc. is a Boston-based company that specializes in leadership and performance coaching. Established in 2017, it has developed a comprehensive digital platform designed to enhance the mental game and mindset of professionals, particularly managers and executives. The platform offers tailored programs, performance coaching, and research-based exercises aimed at fostering peak performance. Additionally, Valor Performance provides progress metrics and a community focused on continuous improvement, ensuring a premium coaching experience that remains scalable. The company is dedicated to bridging the professional training gap through its innovative solutions.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Optimus Ride is a self-driving vehicle company located in Boston, Massachusetts, focused on developing technologies that promote efficient, sustainable, and equitable mobility systems. As a spinoff from the Massachusetts Institute of Technology, the company leverages over 30 years of interdisciplinary research in self-driving technologies, electric vehicles, and Mobility-on-Demand Systems. Optimus Ride specializes in creating self-driving technology systems tailored for geofenced environments, utilizing innovations in complex sensor fusion, mapping, computer vision, and machine learning. The company's expertise is further enhanced by a team with extensive industrial and entrepreneurial experience in manufacturing robots, urban design, and shared vehicle fleet management, allowing it to offer versatile transportation solutions that range from commercial vessel operations to transit options.

Valor Performance, Inc. is a Boston-based company that specializes in leadership and performance coaching. Established in 2017, it has developed a comprehensive digital platform designed to enhance the mental game and mindset of professionals, particularly managers and executives. The platform offers tailored programs, performance coaching, and research-based exercises aimed at fostering peak performance. Additionally, Valor Performance provides progress metrics and a community focused on continuous improvement, ensuring a premium coaching experience that remains scalable. The company is dedicated to bridging the professional training gap through its innovative solutions.

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutic compounds through inhibiting the complement system for treating autoimmune and inflammatory diseases. Its lead product candidate, pegcetacoplan, is in Phase III trials for geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, among other indications.

Buoy Health is a health technology company that develops AI-powered digital health tools to help individuals manage healthcare options. It offers an online healthcare assistant that analyzes symptoms, performs first-line triage, and provides treatment recommendations. Its platform delivers real-time symptom analysis and helps users navigate the healthcare system, research benefits, and locate in-network providers. For employers, the platform surfaces benefits information, guides employees to in-network providers, and integrates with other health portals. Founded in 2014 and based in Boston, Buoy Health aims to resemble a physician-patient conversation through machine learning and proprietary data, enabling users to make informed care decisions.

VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.

Wellframe Inc. is a Boston-based company that specializes in digital care management and health advocacy solutions. Founded in 2011, it partners with health plans across the country to enhance the relationship between healthcare providers and members. Wellframe's offerings include a mobile application that facilitates daily health reporting, a care team dashboard to prioritize patient needs, and an array of communication tools for two-way messaging. The company also provides comprehensive operational services, such as implementation support, recruiting, and analytics. Additionally, Wellframe's platform employs real-time data and artificial intelligence to deliver personalized care protocols, enabling caregivers to monitor patient status effectively and identify when intervention is necessary. By focusing on mobile patient engagement and care management, Wellframe aims to improve health outcomes and empower individuals in managing their health.

Founded in 2014, Compass Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics to treat solid tumors and hematological malignancies. Its pipeline includes CTX-471, an agonistic antibody of CD137 for immune cell activation, currently in Phase I trials; CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, in IND-enabling studies; and CTX-009, a bispecific antibody inhibiting DLL4 and VEGF-A signaling, completed Phase I and is in Phase Ib combination with chemotherapy.

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.

Quovo Inc. is a data platform that specializes in providing financial analytics and data management solutions for small- and mid-sized investors. Founded in 2009 and headquartered in New York, the company enables businesses to connect to millions of consumer financial accounts across over 14,000 institutions. Quovo's platform retrieves, organizes, and analyzes data, offering features such as automated data repair, portfolio reconciliation, and insights into client account activity. Its services are tailored for a diverse clientele, including endowments, foundations, family offices, and financial advisors. By facilitating deeper connectivity and insights, Quovo assists financial service providers in enhancing customer relationships and personalizing their offerings. In 2019, Quovo became a subsidiary of Plaid Inc.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Ivenix, Inc. is a medical technology company based in North Andover, Massachusetts, specializing in the development of advanced intravenous (IV) infusion systems. Founded in 2001 and originally known as Fluidnet Corporation, Ivenix offers a next-generation infusion management platform that utilizes pneumatic technology to enhance the accuracy of fluid delivery. This innovative system is designed to measure and control flow regardless of factors such as bag height, backpressure, patient movement, and fluid viscosity. Additionally, the platform manages patient infusion data and integrates seamlessly with clinical information systems, ensuring precise and continuous infusion delivery in hospital settings. Ivenix aims to revolutionize infusion therapy worldwide by combining state-of-the-art information technology with user-friendly design, thereby improving patient care and safety.

Axoni is a technology company specializing in real-time data replication solutions tailored for the financial industry. Established in 2017, it focuses on serving major financial institutions, including banks, asset managers, hedge funds, and market infrastructure firms worldwide, with offices located in New York and London. The company's platform facilitates the rapid and reliable deployment of critical financial networks, ensuring automated, real-time data replication among market participants. Additionally, Axoni develops distributed ledger software that integrates traditional financial technologies with blockchain capabilities, enhancing market information, trend analysis, and communication networks. This innovative approach allows financial entities to modernize their systems related to legal records, lifecycle events, and cash flow calculations, thereby improving operational efficiency and data management.

TraceLink develops and provides track-and-trace solutions for the life sciences supply chain. Its primary offering is TraceLink Life Sciences Cloud, enabling pharmaceutical serialization and compliance with regulations like EU Falsified Medicines Directive. The company serves pharmaceutical companies, distributors, and repackagers, with strategic partnerships to enhance its services.

Turnstone Biologics is a clinical-stage biotechnology company focused on developing viral immunotherapies to improve cancer survival. Its lead candidate, RIVAL-01, combines three immunomodulators to stimulate immune activity and reprogram the tumor microenvironment.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Codeship Inc. is a provider of hosted continuous integration solutions, specializing in the development and deployment of Docker-based applications. Founded in 2011 and headquartered in Boston, Massachusetts, with an additional office in Vienna, Austria, the company was previously known as Railsonfire Limited before rebranding in January 2013. Codeship's platform is designed to streamline the software development process by automating testing and release tasks, which helps reduce development cycles, minimize the risk of bugs, and foster innovation. As of February 2018, Codeship operates as a subsidiary of CloudBees, Inc. The platform caters specifically to software companies, enabling them to enhance their product development efficiency through a customizable and scalable continuous integration and deployment service.

Founded in 2014, Quartet Health operates a cloud-based platform facilitating communication between medical providers and behavioral health specialists for improved patient care. The platform works with health plans and systems to provide actionable insights on behavioral health conditions, enhancing patient outcomes.

Toast is a cloud-based point-of-sale and restaurant-management platform for the food service and hospitality industry. It offers an end-to-end system that combines front-of-house and back-of-house functionality, including tableside ordering, online ordering, delivery tracking, labor management, and real-time reporting. The platform serves a broad range of establishments such as restaurants, bakeries, cafes, bars, nightclubs, and pizzerias, with a focus on mid-market operators primarily in the United States. Toast generates revenue from the sale of restaurant-grade hardware and recurring subscriptions and services tied to transaction volume. As of fiscal 2024, it served approximately 134,000 restaurant locations, and its typical customer generates slightly more than $1 million in annual revenue. The company is headquartered in Boston and maintains additional offices in Portland, Oregon; Omaha, Nebraska; and Dublin, Ireland.

Codeship Inc. is a provider of hosted continuous integration solutions, specializing in the development and deployment of Docker-based applications. Founded in 2011 and headquartered in Boston, Massachusetts, with an additional office in Vienna, Austria, the company was previously known as Railsonfire Limited before rebranding in January 2013. Codeship's platform is designed to streamline the software development process by automating testing and release tasks, which helps reduce development cycles, minimize the risk of bugs, and foster innovation. As of February 2018, Codeship operates as a subsidiary of CloudBees, Inc. The platform caters specifically to software companies, enabling them to enhance their product development efficiency through a customizable and scalable continuous integration and deployment service.

PatientPing, Inc. is a health technology company that has developed a national care coordination network aimed at enhancing communication among healthcare providers. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers real-time notifications and care guidelines to various healthcare professionals, including physicians, nurses, case managers, and care coordinators. This network spans hospitals, emergency departments, accountable care organizations, physician practices, skilled nursing facilities, home health agencies, and payers. PatientPing's platform includes a tool called Spotlights, which leverages real-time data to analyze utilization and performance trends in patient care. By improving information sharing among care teams, PatientPing facilitates higher quality, cost-effective care, ultimately aiming to enhance patient outcomes and experiences. The company also maintains a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC.

VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Ivenix, Inc. is a medical technology company based in North Andover, Massachusetts, specializing in the development of advanced intravenous (IV) infusion systems. Founded in 2001 and originally known as Fluidnet Corporation, Ivenix offers a next-generation infusion management platform that utilizes pneumatic technology to enhance the accuracy of fluid delivery. This innovative system is designed to measure and control flow regardless of factors such as bag height, backpressure, patient movement, and fluid viscosity. Additionally, the platform manages patient infusion data and integrates seamlessly with clinical information systems, ensuring precise and continuous infusion delivery in hospital settings. Ivenix aims to revolutionize infusion therapy worldwide by combining state-of-the-art information technology with user-friendly design, thereby improving patient care and safety.

Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for serious women's health infections, particularly those that have been historically overlooked. Founded in 2012 and headquartered in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut, the company specializes in antibiotics for gynecologic infections. Its lead product, Solosec (secnidazole), is a next-generation 5-nitroimidazole antibiotic designed for the one-time oral treatment of bacterial vaginosis. This drug is characterized by its enhanced pharmacokinetic properties, allowing for effective and well-tolerated delivery in a single dose. Symbiomix Therapeutics operates as a subsidiary of Lupin Inc.

Dimension Therapeutics, Inc. is a gene therapy company based in Cambridge, Massachusetts, specializing in the development of innovative treatments for rare and metabolic diseases associated with the liver. Founded in 2013, the company has a robust pipeline of gene therapy programs, including DTX101 and DTX201 for hemophilia B and A, respectively. Additionally, its portfolio encompasses DTX301 for ornithine transcarbamylase deficiency, DTX401 for glycogen storage disease type Ia, DTX501 for phenylketonuria, DTX701 for Wilson disease, and DTX601 for citrullinemia type I. Dimension Therapeutics collaborates with REGENX Biosciences, gaining access to a significant portfolio of patents related to adeno-associated virus (AAV) therapeutics. This collaboration supports the company's aim to advance its gene therapy platform and enhance its product development capabilities in the treatment of rare diseases. Dimension Therapeutics operates as a subsidiary of Ultragenyx Pharmaceutical Inc. since November 2017.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.